Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Primary Efficacy Objective: To assess the efficacy of SCH 900222/MK-3222, hereafter referred to as MK-3222, compared to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of subjects with at least 75% improvement in the Psoriasis Area and Severity Index from baseline (PASI 75 response) and the proportion of subjects with a Physician’s Global Assessment (PGA) score of “clear” or “minimal” with at least a 2 grade reduction from baseline at Week 12. Primary Safety/Tolerability Objective: To assess the safety/tolerability of MK-3222 in subjects with moderateto-severe chronic plaque psoriasis at Week 12.
Inclusion criteria
- Moderate To Severe Chronic Plaque Psoriasis